Manufacturer
Merck Sharp & Dohme
Contents
Mometasone furoate
Indication
For use in adults, adolescents and children 3-11 years for the symptomatic treatment of seasonal or perennial rhinitis.
In patients who have a history of moderate to severe symptoms of seasonal allergic rhinitis, prophylactic treatment with Nasonex is recommended 2-4 weeks prior to the anticipated start of the pollen season.
Treatment of nasal polyps in patients ≥18 years.
Treatment of symptoms associated with acute rhinosinusitis in patients ≥12 years without signs or symptoms of severe bacterial infection.
Instruction
Drug interaction
Malaysia
